When is ANIP's latest earnings report released?
The most recent financial report for Ani pharmaceuticals, inc. (ANIP) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANIP's short-term business performance and financial health. For the latest updates on ANIP's earnings releases, visit this page regularly.
Where does ANIP fall in the P/E River chart?
According to historical valuation range analysis, Ani pharmaceuticals, inc. (ANIP)'s current price-to-earnings (P/E) ratio is 21.47, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of ANIP?
According to the latest financial report, Ani pharmaceuticals, inc. (ANIP) reported an Operating Profit of 29.89M with an Operating Margin of 12.1% this period, representing a growth of 390.08% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ANIP's revenue growth?
In the latest financial report, Ani pharmaceuticals, inc. (ANIP) announced revenue of 247.06M, with a Year-Over-Year growth rate of 29.64%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ANIP have?
As of the end of the reporting period, Ani pharmaceuticals, inc. (ANIP) had total debt of 617.04M, with a debt ratio of 0.43. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ANIP have?
At the end of the period, Ani pharmaceuticals, inc. (ANIP) held Total Cash and Cash Equivalents of 285.62M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ANIP go with three margins increasing?
In the latest report, Ani pharmaceuticals, inc. (ANIP) achieved the “three margins increasing” benchmark, with a gross margin of 59.4%%, operating margin of 12.1%%, and net margin of 11.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ANIP's profit trajectory and future growth potential.
Is ANIP's EPS continuing to grow?
According to the past four quarterly reports, Ani pharmaceuticals, inc. (ANIP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ANIP?
Ani pharmaceuticals, inc. (ANIP)'s Free Cash Flow (FCF) for the period is 29.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 116.27% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ANIP?
The latest valuation data shows Ani pharmaceuticals, inc. (ANIP) has a Price-To-Earnings (PE) ratio of 21.47 and a Price/Earnings-To-Growth (PEG) ratio of 3.43. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
